Iomeron (Iomeprol)

Iomeprol provides a high concentration of iodine atoms that absorb X‑ray photons more effectively than surrounding tissues. When injected, it increases the attenuation of X‑rays in the blood vessels and targeted organs, creating a clear difference between enhanced and non‑enhanced areas on the resulting images, thereby improving diagnostic accuracy.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient weight, renal function and the required level of contrast enhancement. Dosing guidelines are provided in the product’s prescribing information and must be individualized for each patient.

The safety of Iomeron in pregnancy and lactation has not been definitively established. It should be used only when the diagnostic benefit outweighs potential risks to the fetus or infant, and after careful consideration by the treating physician. Alternative imaging methods without iodinated contrast may be preferred when feasible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Iomeron. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Its high iodine concentration provides strong X‑ray attenuation, similar to other modern agents such as iohexol or iopamidol, while generally causing fewer discomfort‑related reactions and lower risk of nephrotoxicity.

Iomeron should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze or shake the vial before use. Follow standard aseptic techniques when preparing the injection, and discard any solution that appears discolored or contaminated.

Iomeron is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via intra‑arterial, intra‑articular or intravenous route, depending on the imaging procedure. The appropriate volume is drawn into a syringe, mixed with compatible diluents if required, and injected at the recommended rate to achieve optimal contrast enhancement.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and cardiovascular events like hypotension or arrhythmias. Patients with known iodine allergy, impaired renal function, or uncontrolled thyroid disease should be closely monitored, and emergency measures must be readily available during administration.

Iomeron is contraindicated in patients with a documented hypersensitivity to iomeprol or any component of the formulation, and should be avoided in individuals with severe renal impairment where alternative imaging is possible. Caution is also advised for patients with uncontrolled hyperthyroidism, recent myocardial infarction, or those who are pregnant unless the diagnostic benefit justifies the potential risk.